---
title: A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet
nct_id: NCT07137286
overall_status: RECRUITING
sponsor: Mayo Clinic
study_type: OBSERVATIONAL
primary_condition: LDL Hyper-responsiveness
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07137286.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07137286"
ct_last_update_post_date: 2025-11-20
last_seen_at: "2026-05-12T07:04:23.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet

**Official Title:** Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet

**NCT ID:** [NCT07137286](https://clinicaltrials.gov/study/NCT07137286)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Mayo Clinic
- **Conditions:** LDL Hyper-responsiveness
- **Start Date:** 2025-09-11
- **Completion Date:** 2027-08
- **CT.gov Last Update:** 2025-11-20

## Brief Summary

The purpose of this study is to identify whether individuals following a ketogenic diet who experience extreme LDL-C elevation, termed "hyper-responders", have identifiable genetic variations in genes involved in cholesterol absorption.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years of age or older
* LDL-C \>170 mg/dL in response to starting a ketogenic diet

Exclusion Criteria:

* Patients who do not consent to blood draw for genetic testing
* Those with LDL-C \<170 mg/dL on a ketogenic diet
```

## Primary Outcomes

- **Number of Patients to have a genetic mutation** _(time frame: Baseline)_ — Genetic Mutation will be defined as a mutation in ABCG5, ABCG8, APOB, APOE, CETP, CYP27A1, LDLR, LDLRAP1, LIPA, LPL, LRP6, and PCSK9 genes

## Locations (1)

- Mayo Clinic, Rochester, Minnesota, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mayo clinic|rochester|minnesota|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07137286.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07137286*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*